Abstract 579P
Background
Dacomitinib demonstrated superior survival benefit compared to gefitinib as a first-line treatment in EGFR-mutant non-small cell lung cancer (NSCLC) patients through the phase 3 trial, ARCHER 1050 study. However, there is a lack of real-world data regarding the efficacy of dacomitinib and further sequential treatments after failure of dacomitinib.
Methods
This study included patients with advanced EGFR-mutant NSCLC who received first-line dacomitinib between January 2021 and December 2022 at Samsung Medical Center and St. Vincent Hospital. This study evaluated objective response rate (ORR), progression-free survival (PFS), safety of dacomitinib, and subsequential treatment after failing dacomitinib.
Results
In total, this study included 153 patients, with a median age of 63.7 years. Exon 19 deletion was observed in 50.3%, while the L858R mutation in exon 21 was observed in 46.4% of patients. The ORR was 84.3%. Median follow-up duration was 16.9 months, and the median PFS was 16.7 months (95% CI, 14.4, 25.2). According to type of EGFR mutation, the median PFS was 18.1 months (95% CI, 14.5, not reached) in patients with exon 19 deletion, and 15.9 months (95% CI, 12.5, not reached) in patients with L858R mutation in exon 21. Grade 3 or higher adverse events were observed in 7.2% of patients, with skin rash occurring in 4.6% and diarrhea in 2.0%. Dose reduction of dacomitinib occurred in 85.6% of patients, with a final dose of 30mg in 49.0% and 15mg in 36.6%. Among the 60 patients who experienced disease progression, 32 patients underwent tissue re-biopsy, while among the remaining, 24 patients underwent liquid biopsy. Overall, T790M mutation was detected in 40% of patients who progressed to dacomitinib.
Conclusions
This study highlights the efficacy of dacomitinib as a promising first-line treatment for patients with EGFR-mutant NSCLC in a real-world setting. The detection rate of T790M mutation after dacomitinib treatment failure was similar to that of other 2nd generation EGFR-TKI.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Pfizer.
Disclosure
J.E. Shin: Financial Interests, Institutional, Funding: Pfizer.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract